IGF-1 LR3 vs NA-Selank Amidate
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →NA-Selank Amidate
NA-Selank Amidate (N-Acetyl Selank Amidate) is an enhanced version of Selank with improved stability and blood-brain barrier penetration. The modifications increase bioavailability and duration of cognitive and anxiolytic effects.
Full details →Side-by-Side Comparison
| Aspect | IGF-1 LR3 | NA-Selank Amidate |
|---|---|---|
| Mechanism | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. | Same core mechanism as Selank - modulates BDNF, serotonin, and norepinephrine systems. The N-acetyl group improves membrane permeability while the amidate modification increases enzymatic stability. |
| Typical Dosage | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. | Intranasal: 100-400mcg 1-3 times daily. Lower doses needed compared to standard Selank due to enhanced bioavailability. |
| Administration | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. | Primarily intranasal administration. Can be used sublingually. More stable in solution than standard Selank. |
| Side Effects | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. | Generally well-tolerated. Possible mild fatigue or nasal irritation. Less frequent dosing needed than standard Selank. |
| Best For |